Kenneth Emancipator - Researcher Profile

Publications

3 shown

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon , Naiyer A. Rizvi , Rina Hui +24 more

Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor...

2015 New England Journal of Medicine 6054 citations

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

Kei Muro , Hyun Cheol Chung , Veena Shankaran +15 more

2016 The Lancet Oncology 1096 citations

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

Charlotte Roach , Nancy Zhang , Ellie Corigliano +7 more

A companion diagnostic assay was codeveloped by Dako for pembrolizumab non–small-cell lung cancer clinical trials to detect PD-L1 expression by immunohistochemistry (IHC). This ...

2016 Applied immunohistochemistry & molecu... 346 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 7,496
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-6629-4430

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.